Alumis (ALMS) Cash from Investing Activities (2023 - 2025)
Alumis' (ALMS) quarterly Cash from Investing Activities came in at $95.0 million in Q4 2025, up 206.99% year-on-year from $31.0 million in Q4 2024, and up 295.29% on a QoQ basis from $24.0 million in Q3 2025.
Alumis (ALMS) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Cash from Investing Activities data on file, last reported at $95.0 million in Q4 2025.
- On a quarterly basis, Cash from Investing Activities rose 206.99% year-over-year to $95.0 million in Q4 2025; TTM through Dec 2025 was $287.9 million, a 352.99% increase from a year earlier, with the FY2025 full-year figure at $287.9 million, up 352.99% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at $95.0 million, up from $24.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ALMS reached as high as $129.4 million in Q2 2025 and fell as low as -$93.2 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged $17.8 million across 3 years, with a median of $15.8 million in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 846.86% in 2024 and fell as far as 1330.06% in 2024.
- Year by year, Cash from Investing Activities stood at -$4.1 million in 2023, then jumped by 846.86% to $31.0 million in 2024, then soared by 206.99% to $95.0 million in 2025.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $95.0 million in Q4 2025, $24.0 million in Q3 2025, and $129.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Alumis | 2.37 Bn | 2.06 Bn | - | 95.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 95.01 Mn |
| Dec 31, 2025 | 95.01 Mn |
| Sep 30, 2025 | 24.04 Mn |
| Sep 30, 2025 | 24.04 Mn |
| Jun 30, 2025 | 129.40 Mn |
| Jun 30, 2025 | 129.40 Mn |
| Mar 31, 2025 | 39.43 Mn |
| Mar 31, 2025 | 39.43 Mn |
| Dec 31, 2024 | 30.95 Mn |
| Dec 31, 2024 | 30.95 Mn |
| Sep 30, 2024 | -93.19 Mn |
| Sep 30, 2024 | -93.19 Mn |
| Jun 30, 2024 | -32.74 Mn |
| Jun 30, 2024 | -32.74 Mn |
| Mar 31, 2024 | -18.81 Mn |
| Mar 31, 2024 | -18.81 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Sep 30, 2023 | 7.58 Mn |
| Sep 30, 2023 | 7.58 Mn |